Given the morbidity and mortality associated with multiple sclerosis, as well as the high cost of treating the acute attacks and disability of MS disease, treatment with IFN β-1a SC injection, IFNβ-1b SC injection, and glatiramer acetate is relatively cost-effective. Life time treatment of multiple sclerosis patients can cost as much as 2.2 million US dollar. Controlling acute attack can reduce the economic burden of MS disease.
Multiple sclerosis cost-effectiveness of therapy
Encephalopathy cost-effectiveness of therapy
Multiple sclerosis alternative therapies
Systemic lupus erythematosus cost-effectiveness of therapy
Tuberous sclerosis cost-effectiveness of therapy
Alzheimer's disease future or investigational therapies
Multiple sclerosis tertiary prevention
Migraine cost-effectiveness of therapy